Xencor Inc (XNCR) · Oct 26, 2026 · Other events

Xencor clinical results clear the bar for XmAb819 kidney cancer study

Above the bar — 400 μg/kg cORR 45.5%; ~82% six-month PFS estimate

Xencor’s XmAb819 clinical results show a 45% response rate in heavily pretreated kidney cancer, supporting a pivotal-study path in 2027.

Xencor is a cash-funded clinical-stage biotech building a pipeline around bispecific T-cell engagers, with XmAb819 now its internally owned lead solid-tumor program and a potential registration-enabling study targeted for 2027. The company has previously described sufficient cash to fund development into 2028, while this filing extends that runway framing into 2029.

The efficacy signal is meaningfully better than the usual Phase 1 proof-of-concept bar. In heavily pretreated clear-cell renal-cell carcinoma—every patient had prior checkpoint-inhibitor and VEGFR-TKI exposure—the 400 μg/kg cohort produced a 45.5% confirmed response rate in 11 evaluable patients, with 81.8% disease control and only 18.2% primary progression (Efficacy — 400 μg/kg). The broader expansion-dose data also show 45.2% response in patients previously treated with at least two VEGFR-TKIs, the subgroup most relevant to a potential accelerated-approval strategy. 〔0〕

The durability and disease-control details strengthen the headline response rate. Across the consolidated target-dose population, median time on treatment was 7.9 months, the six-month progression-free-survival estimate was approximately 82%, and the median PFS had not been reached (Additional Results). Those are early, non-randomized data, but they suggest the drug is not merely producing shallow or fleeting tumor shrinkage. The filing also reports that 19 of 25 responders in the expansion cohorts remained on response at the data cut. 〔1〕

The filing changes XmAb819’s role from promising Phase 1 asset to credible pivotal candidate. Xencor has completed enrollment in the 400 μg/kg expansion cohort, designates that dose as the proposed recommended Phase 3 dose, and plans an end-of-Phase-1 meeting with regulators in the first half of 2027. It is also laying out a randomized study against tivozanib that could support a post-immunotherapy/post-TKI label, subject to regulatory agreement. 〔2〕

Safety is workable but not clean, so the pivotal study must prove the benefit-risk balance. Rash affected 91.2% of expansion-dose patients, grade 3-or-higher adverse events occurred in 82.4%, and serious adverse events occurred in 61.8% (Adverse events). The counterpoint is that discontinuation due to adverse events was 7.4%, no treatment-related deaths were reported, and cytokine-release syndrome was described as predominantly low-grade and concentrated during priming. The regimen still appears operationally manageable, but it will require step-up dosing, premedication, and close monitoring.

The comparison to existing therapies is directionally favorable but not definitive. Xencor’s cross-trial comparisons show a 45% response rate above historical monotherapy benchmarks in later-line kidney cancer, but the company explicitly warns that these are not head-to-head studies. The real validation point is therefore the upcoming randomized trial, not the historical comparison itself.

Bottom line: This filing materially advances Xencor’s business story: XmAb819 now has a strong enough efficacy and durability profile to justify a pivotal-development push in an underserved, heavily pretreated population. The main remaining question is whether the safety burden and small, non-randomized dataset hold up in the larger 2027 development program.

What to watch next

Full 400 μg/kg data and Phase 1 meeting, 1H 2027

Original filing on SEC EDGAR

More Xencor Inc news

• Xencor earnings beat as cash runway extends and XmAb819 advances